Millard H Lambert

List of Publications by Year
in descending order

46	14,035	87888 38	233421 45
papers	citations	h-index	g-index

46	46	46	12004
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	D3R Grand Challenge 3: blind prediction of proteinâ€“ligand poses and affinity rankings. Journal of Computer-Aided Molecular Design, 2019, 33, 1-18.	2.9	104
2	Structure of Rev-erbÎ± bound to N-CoR reveals a unique mechanism of nuclear receptorâ€“co-repressor interaction. Nature Structural and Molecular Biology, 2010, 17, 808-814.	8.2	80
3	Substituted 2-[(4-Aminomethyl)phenoxy]-2-methylpropionic Acid PPARÎ± Agonists. 1. Discovery of a Novel Series of Potent HDLc Raising Agents. Journal of Medicinal Chemistry, 2007, 50, 685-695.	6.4	115
4	Co-crystal structure guided array synthesis of PPARÎ³ inverse agonists. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3916-3920.	2.2	20
5	A Critical Assessment of Docking Programs and Scoring Functions. Journal of Medicinal Chemistry, 2006, 49, 5912-5931.	6.4	1,429
6	X-ray Crystal Structures of the Estrogen-related Receptor-Î³ Ligand Binding Domain in Three Functional States Reveal the Molecular Basis of Small Molecule Regulation. Journal of Biological Chemistry, 2006, 281, 37773-37781.	3.4	120
7	Substrate Specificity and Novel Selective Inhibitors of TNF-α Converting Enzyme (TACE) from Two-Dimensional Substrate Mapping. Combinatorial Chemistry and High Throughput Screening, 2005, 8, 327-339.	1.1	24
8	Structural Disorder in the Complex of Human Pregnane X Receptor and the Macrolide Antibiotic Rifampicin. Molecular Endocrinology, 2005, 19, 1125-1134.	3.7	185
9	A Ligand-mediated Hydrogen Bond Network Required for the Activation of the Mineralocorticoid Receptor. Journal of Biological Chemistry, 2005, 280, 31283-31293.	3.4	188
10	Progesterone Receptor Ligand Binding Pocket Flexibility:â€‰ Crystal Structures of the Norethindrone and Mometasone Furoate Complexes. Journal of Medicinal Chemistry, 2004, 47, 3381-3387.	6.4	78
11	A Structural Basis for Constitutive Activity in the Human CAR/RXRÎ± Heterodimer. Molecular Cell, 2004, 16, 919-928.	9.7	219
12	Crystal Structures of the Catalytic Domain of Phosphodiesterase 4B Complexed with AMP, 8-Br-AMP, and Rolipram. Journal of Molecular Biology, 2004, 337, 355-365.	4.2	113
13	Activation of Nuclear Receptors. Structure, 2003, 11, 741-746.	3.3	161
14	Novel selective small molecule agonists for peroxisome proliferator-activated receptor Î´ (PPARÎ´)â€”synthesis and biological activity. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1517-1521.	2.2	301
15	The Drosophila Orphan Nuclear Receptor DHR38 Mediates an Atypical Ecdysteroid Signaling Pathway. Cell, 2003, 113, 731-742.	28.9	226
16	Subtype Specific Effects of Peroxisome Proliferator-Activated Receptor Ligands on Corepressor Affinity. Biochemistry, 2003, 42, 9278-9287.	2.5	44
17	X-ray Crystal Structure of the Liver X Receptor Î²2 Ligand Binding Domain. Journal of Biological Chemistry, 2003, 278, 27138-27143.	3.4	187
18	Identification of a Novel Human Constitutive Androstane Receptor (CAR) Agonist and Its Use in the Identification of CAR Target Genes. Journal of Biological Chemistry, 2003, 278, 17277-17283.	3.4	380

#	Article	IF	Citations
19	The first completed genome sequence from a teleost fish (Fugu rubripes) adds significant diversity to the nuclear receptor superfamily. Nucleic Acids Research, 2003, 31, 4051-4058.	14.5	137
20	Structural insights into regulation of nuclear receptors by ligands. Nuclear Receptor Signaling, 2003, 1, nrs.01004.	1.0	13
21	Structural Mechanisms of Ligand-Mediated Signaling by Nuclear Receptors. , 2003, , 21-24.		0
22	Pregnane X Receptor (PXR), Constitutive Androstane Receptor (CAR), and Benzoate X Receptor (BXR) Define Three Pharmacologically Distinct Classes of Nuclear Receptors. Molecular Endocrinology, 2002, 16, 977-986.	3.7	319
23	Interactions that determine the assembly of a retinoid X receptor/corepressor complex. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 5842-5847.	7.1	42
24	Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition. Cell, 2002, 110, 93-105.	28.9	747
25	Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARÎ±. Nature, 2002, 415, 813-817.	27.8	598
26	Design, Structure, and Function of Novel PPAR Ligands. Medical Science Symposia Series, 2002, , 5-8.	0.0	1
27	Peroxisome Proliferatorâ€“Activated Receptor Î³ and Metabolic Disease. Annual Review of Biochemistry, 2001, 70, 341-367.	11.1	552
28	Design of Selective and Soluble Inhibitors of Tumor Necrosis Factor-Î± Converting Enzyme (TACE). Journal of Medicinal Chemistry, 2001, 44, 4252-4267.	6.4	70
29	Pharmacophore Analysis of the Nuclear Oxysterol Receptor LXRÎ±. Journal of Medicinal Chemistry, 2001, 44, 886-897.	6.4	118
30	The Human Nuclear Xenobiotic Receptor PXR: Structural Determinants of Directed Promiscuity. Science, 2001, 292, 2329-2333.	12.6	743
31	N-Hydroxyformamide peptidomimetics as TACE/Matrix metalloprotease inhibitors: oral activity via P1â€² isobutyl substitution. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2147-2151.	2.2	22
32	Identification of a series of oxadiazole-substituted Î±-isopropoxy phenylpropanoic acids with activity on PPARÎ±, PPARÎ³, and PPARÎ´. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2385-2388.	2.2	40
33	Synthesis and biological activity of l-tyrosine-based PPARÎ³ agonists with reduced molecular weight. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 3111-3113.	2.2	32
34	TACE and other ADAM proteases as targets for drug discovery. Drug Discovery Today, 2001, 6, 417-426.	6.4	158
35	Alteration of a Single Amino Acid in Peroxisome Proliferator-Activated Receptor-Î± (PPARÎ±) Generates a PPARÎ´ Phenotype. Molecular Endocrinology, 2000, 14, 733-740.	3.7	71
36	Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix. Genes and Development, 2000, 14, 2229-2241.	5.9	120

#	Article	IF	Citations
37	The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged during Evolution. Molecular Endocrinology, 2000, 14, 27-39.	3.7	607
38	Asymmetry in the PPARÎ³/RXRÎ± Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors. Molecular Cell, 2000, 5, 545-555.	9.7	547
39	Atomic Structure of PDE4: Insights into Phosphodiesterase Mechanism and Specificity. Science, 2000, 288, 1822-1825.	12.6	342
40	Specific Sequence Elements Are Required for the Expression of Functional Tumor Necrosis Factor-Î±-converting Enzyme (TACE). Journal of Biological Chemistry, 1999, 274, 30563-30570.	3.4	145
41	Molecular Recognition of Fatty Acids by Peroxisome Proliferatorâ€“Activated Receptors. Molecular Cell, 1999, 3, 397-403.	9.7	1,052
42	Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-Î³. Nature, 1998, 395, 137-143.	27.8	1,818
43	Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-Î±. Nature, 1997, 385, 733-736.	27.8	1,636
44	Pattern recognition in the prediction of protein structure. I. Tripeptide conformational probabilities calculated from the amino acid sequence. Journal of Computational Chemistry, 1989, 10, 770-797.	3.3	56
45	Pattern recognition in the prediction of protein structure. II. Chain conformation from a probability-directed search procedure. Journal of Computational Chemistry, 1989, 10, 798-816.	3.3	40
46	Pattern recognition in the prediction of protein structure. III. An importance-sampling minimization procedure. Journal of Computational Chemistry, 1989, 10, 817-831.	3.3	35